Pfizer Inc. (PFE) Announces Top-Line Results of Prevenar 13® Phase 3 Trial in Adults 18 to 49 Years of Age
10/4/2012 10:31:14 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13®* (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. These data support a recent regulatory submission to expand the indication of Prevenar 13 in the European Union to include adults between 18 and 49 years old, and will be used to support similar planned submissions in other countries around the world in the future.
comments powered by